Answers are grounded in this paper and cite their sources.
AIM: Current research is focused on developing phospholipid-based nanolipidic carrier (NLC) to deliver lapatinib (LNB) and imatinib (INB) to MDA-MB-231 breast cancer cells and an in vivo mammary tumor model. MATERIALS AND METHODS: Breast cancer (BC) was induced in female rats via the chemical carcinogen 7, 12-dimethylbenz(a)anthracene (DMBA). The dual drug-loaded phospholipid-based NLC were made via a hot microemulsion process. The developed NLC were also characterized, and tested in vitro, in vivo, and in a preclinical setting in a DMBA-induced rat model. RESULTS: The dual drug-loaded phospholipid NLC exhibited favorable nanometric size (279.7 nm, PDI 0.323), high entrapment efficiency (94.21%), and robust loading capacity (13.11%). It achieved biphasic drug release (52.67% at 4 h; 92.12% cumulative), potent cytotoxicity with maximal IC₅₀ reduction at 48 h, and maintained stability under accelerated conditions. In vivo, it significantly reduced tumor burden, normalized hematological and biochemical markers, and demonstrated therapeutic efficacy in DMBA-induced breast cancer, highlighting its translational potential. CONCLUSIONS: The dual drug-loaded NLC not only achieved high entrapment efficiency but also enhanced cytotoxicity against MDA-MB-231 cells and significantly reduced tumor progression. The developed lipid-based nanocarrier system demonstrates strong potential as a targeted platform for the co-delivery of kinase inhibitors, addressing the therapeutic limitations associated with monotherapy and conventional drug formulations.
No takes yet. Share an insight, caveat, or question.
Alruwaili et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: